(CercleFinance.com) – Janssen, the pharmaceutical subsidiary of Johnson & Johnson, announced on Friday that it has filed an application with the Food and Drug Administration (FDA) for the authorization of Stelara in the treatment of juvenile psoriatic arthritis .
Juvenile arthritis is a group of rheumatic diseases, which begins before the age of 16, associating arthritis, fever, rashes, and which affects between 20 and 45 in 100,000 children in the United States, of which 5% are affected by psoriatic form of the disease.
Stelara, a monoclonal antibody, is already approved for the treatment of moderate to severe plaque psoriasis in adults, but also for ulcerative colitis in adults.
The FDA’s decision on juvenile psoriatic arthritis will come in 2022, Janssen said in a statement.
– .
